TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31317668
Drug: Lyophilized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized formulation of Mepolizumab
Study: 31317668
Drug: On-treatment adverse
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment adverse events
Study: 17269591
Drug: Contemporary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contemporary treatment of gynecomastia
Study: 10357727
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg orlistat 3 times daily
Study: 7589634
Drug: hMG and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG and GH (any dose)
Study: 30830077
Drug: Travoprost (0.004%)
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Travoprost (0.004%) monotherapy
Study: 25247485
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HD-DXM) with low-dose dexamethasone maintenance (HD-DXM-M group)
Study: 25247485
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HD-DXM) without low-dose dexamethasone maintenance (HD-DXM-nM group)
Study: 25247485
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone with low-dose dexamethasone maintenance (HD-DXM-M group)
Study: 19227171
Drug: Butorphanol 2
Normalized name: butorphanol 2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2 mg x day(‐1) + morphine 3.3 mg x day(‐1) (group MB)
Study: 19227171
Drug: Morphine 3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 3.3 mg x day(‐1) alone (group M)
Study: 19227171
Drug: Butorphanol 2
Normalized name: butorphanol 2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2 mg x day(‐1) alone (group B)
Study: 16338599
Drug: Magnesium (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (450 mg/day)
Study: 11244702
Drug: Mivacurium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.2 mg.kg‐1) with non-invasive blood pressure measurement in the ipsilateral arm
Study: 9286852
Drug: Mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 100 mg once daily for 3 weeks
Study: 9286852
Drug: Mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 100 mg once daily
Study: 9286852
Drug: Diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem SR 120 mg twice daily
Study: 3553586
Drug: Diclofenac (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75, 100, or 125 mg/day)
Study: 3553586
Drug: Indomethacin (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75, 100, or 125 mg/day)
Study: 22615841
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored guided self‐help treatment targeting depression and comorbid symptoms
Study: 22615841
Drug: Standardized (non‐tailored)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized (non‐tailored) Internet‐based treatment for depression
Study: 15380292
Drug: Tiagabine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (4 mg)
Study: 15380292
Drug: Tiagabine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (8 mg)
Study: 17715212
Drug: Tiagabine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (12 mg)
Study: 17715212
Drug: Tiagabine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (16 mg)
Study: 8851614
Drug: Oral fleroxacin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fleroxacin; single-dose trial; specific dosage not mentioned.
Study: 1519232
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (5.000 anti XaU once daily)
Study: 1519232
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (5.000 IU three times daily)
Study: 6666231
Drug: ISDN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN treatment (240 mg daily, 6 X 40 mg)
Study: 6666231
Drug: ISDN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN treatment
Study: 26555148
Drug: NMES treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMES treatment group (8-week daily NMES treatment)
Study: 26555148
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual or conventional treatments)
Study: 24789375
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate eyedrops, 1% (1 drop daily)
Study: 24789375
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Patching and Atropine)
Study: 22078979
Drug: Irbesartan/hydrochlorothiazide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/hydrochlorothiazide (150 mg/12.5 mg day)
Study: 22078979
Drug: Nebivolol/hydrochlorothiazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol/hydrochlorothiazide (5 mg/12.5 mg day)
Study: 19284181
Drug: Colloidal-Q10 (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal-Q10 (new formulation)
Study: 19284181
Drug: Oil-based formulation
Normalized name: phenylephrine hydrochloride / shark liver oil Rectal Cream [Formulation R]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-based formulation
Study: 2294263
Drug: Papaverine (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (18 mg)
Study: 13094
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg iv chlorpheniramine
Study: 13094
Drug: 5.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5 mg/kg iv aminophylline
Study: 13094
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg po chlorpheniramine
Study: 13094
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg po butabarbital
Study: 16847150
Drug: hsCRP 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP 1 to 3 mg/L
Study: 27591455
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (Ropivacaine 0.15% plus Sufentanil 0.2μg/mL solution at 5mL/h)
Study: 27591455
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (Ropivacaine 0.1% plus Sufentanil 0.2μg/mL at 10mL/h)
Study: 27591455
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (Same solution as group A)
Study: 27591455
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (Group A)
Study: 22408272
Drug: Spinal mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal mixture of bupivacaine and morphine followed by oral oxycodone
Study: 19597422
Drug: Plerixafor (0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (0.24 mg/kg) and G-CSF (10 microg/kg for 4 days)
Study: 16162699
Drug: Inhaled glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoids (fluticasone propionate, 1,000 microg/d) for 4 weeks
Study: 11409425
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (t-PA) in patients with Apo E2 phenotype (27 patients)
Study: 11409425
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (t-PA) in patients without Apo E2 phenotype (190 patients)
Study: 3406540
Drug: Intravitreal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal infusion of thrombin
Study: 2021881
Drug: Regular aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aqueous beclomethasone dipropionate (BDP) nasal spray (800 micrograms)
Study: 2021881
Drug: As required
Normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: As required aqueous beclomethasone dipropionate (BDP) nasal spray (800 micrograms)
Study: 329786
Drug: perphenazine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: perphenazine, 20 mg/day
Study: 329786
Drug: amitriptyline, 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline, 125 mg/day with perphenazine, 20 mg/day
Study: 31601530
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First with assertive community treatment (HF-ACT)
Study: 27699657
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate 15 mg/day, sulfasalazine 1 g/day, and HCQ 400 mg/day)
Study: 27699657
Drug: Hydroxychloroquine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine monotherapy (HCQ 400 mg/day)
Study: 17675277
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg alpha-linolenic acid per day
Study: 11642634
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b (10 MU/m2) and lamivudine (4 mg/kg, max 100 mg) for 6 months (Group 1)
Study: 11642634
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b (10 MU/m2) and lamivudine (4 mg/kg, max 100 mg) for 12 months (Group 2)
Study: 9699707
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus slow-release melatonin
Study: 2646266
Drug: Megestrol 40
Normalized name: megestrol 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol 40 mg PO tid
Study: 2646266
Drug: Diethylstilbestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES) 1 mg PO tid
Study: 31220256
Drug: Oral antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antimicrobial regimen (colistin 2×10^6 IU 4×/day, gentamicin 80 mg 4×/day, fosfomycin 3 g every 72 h)
Study: 31220256
Drug: Oral antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antimicrobial regimen
Study: 23421731
Drug: Amitriptyline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 0.5 mg/kg/d
Study: 23421731
Drug: Topiramate 25
Normalized name: topiramate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 25 mg/d increasing up to 100 mg/d
Study: 16716324
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 3-6 months
Study: 16716324
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for >6 months
Study: 16716324
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment overall
Study: 15477546
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis extract
Study: 11740797
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with anti-CD4 monoclonal antibodies or anticytokine agents
Study: 11740797
Drug: T-cell vaccination
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell vaccination and T-cell receptor peptide vaccination targeting autoreactive T cells
Study: 7888291
Drug: Budesonide and
Normalized name: Budesonide and formoterol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and Fluticasone (both doses)
Study: 3283296
Drug: Propranolol-LA (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol-LA (long-acting formulation) at doses of 160, 240, and 320 mg once daily
Study: 3283296
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol at 80 mg three times daily
Study: 30298552
Drug: Fluid loading
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid loading (1 g sodium chloride/125 mL of water starting 2.5-h before LBNP)
Study: 24022566
Drug: L-arginine (20g)
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (20g)
Study: 20404219
Drug: Amlodipine-valsartan combination
Normalized name: amlodipine / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine-valsartan combination (5/80 mg and then 10/160 mg)
Study: 20404219
Drug: Amlodipine-atenolol combination
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-atenolol combination (5/50 mg and then 10/100 mg)
Study: 20404219
Drug: Amlodipine-valsartan combination
Normalized name: amlodipine / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine-valsartan combination
Study: 15802904
Drug: omega3 fatty
Normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega3 fatty acid‐enhanced supplement
Study: 15802904
Drug: arginine‐enhanced supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: arginine‐enhanced supplement
Study: 31471180
Drug: TXA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA plus topical and intravenous CSS (Group A)
Study: 31471180
Drug: TXA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA plus topical CSS only (Group B)
Study: 31471180
Drug: TXA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA plus intravenous CSS only (Group C)
Study: 27521928
Drug: Intrauterine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine administration of autologous PBMCs activated by HCG (n=93)
Study: 27521928
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ET without intrauterine administration) (n=105)
Study: 20055695
Drug: Twice-weekly tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly tacrolimus ointment
Study: 20055695
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (vehicle ointment)
Study: 8744659
Drug: CSE analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE analgesia with a single subarachnoid injection of 1 mg bupivacaine plus 5 micrograms sufentanil and 25 micrograms epinephrine (total volume, 2.5 mL)
Study: 8157042
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon (1 mg)
Study: 8243872
Drug: Subcutaneous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous glucagon (0.5 mg)
Study: 8243872
Drug: Subcutaneous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous glucagon
Study: 3549893
Drug: Relaxation response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relaxation response technique practiced daily for four to six weeks
Study: 24719431
Drug: Weekly text-message
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text-message 'check-in' intervention
Study: 9664766
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (0.01 mg/kg) and hydroxyzine hydrochloride (1mg/kg) intramuscularly
Study: 6340971
Drug: Oxaprozin 1200
Normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaprozin 1200 mg once daily
Study: 8565037
Drug: Nabumetone 1000
Normalized name: nabumetone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1000 mg once daily
Study: 31863182
Drug: Comprehensive multicomponent
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive multicomponent behavioral treatment (Beh)
Study: 31863182
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of behavioral treatment and medication management (Comb&MedMgt)
Study: 11265923
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Comb)
Study: 25015006
Drug: Clonidine 5
Normalized name: apraclonidine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 5 μg/kg every 6 hours
Study: 7019928
Drug: Sisomicin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisomicin (2.5 to 4.0 mg/kg per day for 5 to 21 days)
Study: 7019928
Drug: Tobramycin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (2.5 to 4.0 mg/kg per day for 5 to 21 days)
Study: 29344387
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI) 40 U daily or 80 U every other day for 8 weeks, followed by open-label extension with 16, 40 or 80 U RCI 1-3 times/week for 52 weeks.
Study: 26095443
Drug: Multidisciplinary rehabilitative
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitative care (task-oriented exercises, cognitive-behavioral training, and occupational therapy)
Study: 17415652
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (including interferon monotherapy, pegylated-interferon monotherapy, consensus-interferon, interferon + ribavirin, pegylated-interferon + ribavirin)
Study: 15234664
Drug: 15% paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% paromomycin plus 12% methylbenzonium chloride (PR‐MBCL) applied twice daily for 30 days
Study: 15234664
Drug: 15% paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% paromomycin plus 10% urea (PR‐U) applied twice daily for 30 days
Study: 11398169
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors as second-line therapy for postmenopausal women with advanced breast cancer progressing during tamoxifen therapy.
Study: 11398169
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors as first-line therapy in place of tamoxifen.
Study: 11398169
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors in the prevention of breast cancer and in neoadjuvant and adjuvant treatment of early-stage breast cancer.
Study: 7989475
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for 4 months; mean BMI of treated subgroup: 42.7 ± 4.3 kg/m2.
Study: 3044515
Drug: Proguanil hydrochloride
Normalized name: Proguanil Hydrochloride
DrugBank: Proguanil (DB01131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proguanil hydrochloride (100 mg daily according to weight)
Study: 3044515
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 or 2 tablets daily)
Study: 21198772
Drug: Propofol (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.35 mg kg(‐1))
Study: 21198772
Drug: Midazolam (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.035 mg kg(‐1))
Study: 21198772
Drug: Ketamine (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.30 mg kg(‐1))
Study: 18220290
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2a plus oral placebo for 48 weeks
Study: 16154709
Drug: Overall cortisol
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall cortisol secretion (AUC(G))
Study: 14583678
Drug: Loperamide (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (24 mg) with Quinidine (800 mg)
Study: 14583678
Drug: Loperamide (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (24 mg) without Quinidine (placebo)
Study: 9383184
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg sustained-release verapamil
Study: 9675624
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg chlorthalidone
Study: 1388337
Drug: Droperidol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1.25 mg IV)
Study: 1388337
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg IV)
Study: 29909432
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 50 mg sildenafil
Study: 29909432
Drug: Supralingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supralingual administration of 50 mg sildenafil
Study: 22776958
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant human erythropoietin (rEpo) 3 × 3,000 U/kg within 42 h after birth
Study: 16109111
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg plus naproxen sodium 500 mg
Study: 16109111
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 500 mg
Study: 1701802
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 3 injections/week for 13 weeks)